CONDENSATION PRODUCTS OF 2,2,4-TRIMETHYL-1,2-DIHYDRO-QUINOLINE AND OXO COMPOUNDS AND DERIVATIVES THEREOF

Abstract: There are provided new compounds of general formula (I) obtained by the condensation of 2,2,4-trimethyl-1,2-dihydro-quinoline or salts thereof with an oxo derivative of the general formula R1R2CO, wherein R1 stands for optionally substituted C1-4 alkyl and R2 stands for optionally substituted C1-2 alkyl, X stands for hydrogen or SO3Me, wherein Me stands for hydrogen, alkali or alkali earth metal ion, Y stands for hydrogen or acyl. The new compounds can be used as antioxidants, and particularly for increasing coccidiostatic effect.

Description: CONDENSATION PRODUCTS OF 2,2,4-TRIMETHYL-l,2-DIHYDR0-QUIN0LINE AND 0X0 COMPOUNDS AND DERIVATIVES THEREOF The present invention relates to new condensation products of 2,2,4-trimethyl-l,2-dihydro-quinoline with oxo compounds and the derivatives of same as well as a process for the preparation thereof and fodders and fodder pre ixes con¬ taining said compounds as well as pharmaceutical compositions containing as active ingredient the new compounds. In the last decades the significance of the use of antioxidaπts has increased all over the world in various fields and consequently, the use of the antioxidants has been widely spread. Antioxidants are most often used in rubber industry and in plastic industry and in this field the highest requirement is the specific effectivity of the antioxidants and in addition a very important factor is compatibility as well as small sensibility to migration etc. The use of anti¬ oxidants in agriculture, food industry and recently in veterinary science and human therapy has increased signifi¬ cantly. While in rubber and plastic industry several amine and phenol type antioxidants are used for the stabilization of fodders, practically only 6-ethoxy-l,2-dihydro-2,2,4-tri- methyl-quinoline (E Q) and 2,6-di-tertiary butyl-hydroxy- toluene (BHT) have been used. The antioxidants suitable for the stabilization of fodder mixtures have to meet simul¬ taneously several essential requirements, such as wide spectrum, low toxicity, respective no damage in optimal case. The last point of view is considered in the recommendation of WH0/FA0 Nutrition Meeting Series No. 40 A, B, C, WH0/F0D AU 67.29, according to which such antioxidants should be used for the mentioned purposes, the LD5 Q value of which exceeds 5 g/kg body weight. It is known that either EMQ nor BHT meets this requirement. In spite of this fact these two compounds have been most accepted according to the present state of art. These two compounds are the best in meeting said complex requirements. 6,6'-methylene-bis(2,2, -trimethyl-l,2-dihydro- quinoline) is rather used in human therapy due to its radio- sensibilizing properties and it has proved to be really suit¬ able for the stabilization of fodders as due to the extreme sensibility of its -methylene group very often a colourization occurred in the fatty tissue of the animals. The antioxidant activity of 6,6'-ethylydene-bis(2,2,4- trimethyl-l,2-dihydro-quinoline) called as XAX- is suitable, its toxicity is low, but upon oxidation the ethylydene group is also oxidized and has a certain colourizing effect. A further disadvantage of XAX-M prepared according to Hungarian patent specification No. 162,358 is that the product is not homogeneous chemically, but according to page 4 of the Hungarian patent specification the polycondensatioπ degree, i.e. the number of dihydro-quinoline units changes depending upon the reaction conditions. The products obtained by acet- aldehyde or higher aldehyde condensation form a mixture of condensed molecules containing 2 to 4 dihydro quinoline units. A constant composition cannot be easily ensured, although this is required by the user. No economic and in practice applicable process has been found so far. DOS 35 40 105 relates to the same product and to its property increasing the coccidiostatic activity of known coccidiostatics. The present invention was aimed to find a new com¬ pounds reserving the good antioxidant activity of the known dihydro-quinoline derivatives, but simultaneously to obtain a new product of chemically homogeneous structure being suitable for human and veterinary use increasing the activity of coccidiostatics and showing low toxicity. The new compounds should be prepared by an economic technology in high purity. We have now found that new compounds meeting the above requirements can be. prepared if 2,2,4-trimethyl-l,2-dihydro- quinoliπe is condensed under special reaction conditions with lower ketones and if desired the obtained compounds are sulfonated and/or acylated. According to the present invention new compounds of the general Formula (I) and acid addition salts thereof are prepared - wherein R 1 stands for optionally substituted alkyl and R 2 stands for optionally substituted alkyl, X stands for hydrogen or 50 Me - wherein Me stands for hydrogen, alkali or alkali earth metal ion, Y stands for hydrogen or acyl. The new compounds can be prepared by condensing aceto- anil (2,2,4-trimethyl-l,2-dihydro-quinoline) or salts thereof with an oxo derivative of the general Formula R- R 2 C0 - wherein R^- and R 2 are as defined above, in the presence of 1-5 h , preferably 2-3 h nitrogen containing base as a cocatalyst, preferably triethanol amine, pyridine or anyline and in the presence of a mineral acid, preferably 0.9-2.5 mole, prefer¬ ably 1.25-1.75 mole hydrochloric acid as a catalyst related to the dihydro quinoline in a solvent and if desired converting the obtained product to acid addition salt or setting free the free base from the salt and if desired sulfonatiπg and/or acylating the obtained base with sulfuric acid or oleum. The acid addition salts can be formed with an acid, such as hydrochloric acid, hydrogen bromide or sulfuric acid, preferably hydrochloric acid. In the meaning of R-*- the alkyl groups can be straight or branched and can stand for an optionally substituted C^.^ alkyl, preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec.butyl, preferably methyl, ethyl cr isobutyl. The substitueπts can be selected from hydroxyl, halogen, C^_^ alkoxy, carboxyl and C^_4 alkoxy-carbonyl. R 2 may preferably stand for alkyl, preferably methyl, ethyl, which can be substituted with the same groups as given for R-*-. X preferably stands for hydrogen or SO^Me, wherein Me stands for alkali or alkali earth metal ion, preferably sodium, potassium or calcium ion. Y preferably stands for hydrogen or an acyl group, preferably acetyl, formyl, benzoyl, particularly acetyl. Surprisingly the use of a nitrogen containing base results in a quick condensation and thus the formation of side products is eliminated. In the course of condensation the reaction medium is the ketone itself in an amount of 0-40 % containing preferably 10-20 h of water. Sulfonation can be carried out by methods known per se using oleum or sulfuric acid. Acylatioπ can be performed with known acylating agents such as acetic anhydride, acetyl chloride, benzoyl chloride, formyl chlorice etc. The reaction mixture can be worked up by filtering the salt, preferably the hydrochloride and by centrifuging and converting it into free base. A product of a purity higher than 95 H is obtained. According to another method the product is worked up together with the mother liqueur, whereafter the unreacted starting material is distilled off in vacuo and thus a product of 60-80 h purity is obtained. It shows that a pure product is obtained without crystallization. The reaction is carried out at a temperature ranging from room temperature to the boiling point of the mixture, optionally under pressure. As a ketone preferably acetone, methyl ethyl ketone or methyl isobutyl ketone, particulary acetone is used. The molar ratio of the reactaπt related to acetoaπil is generally ranging from 0.5 mole to a several fold excess. Preferably a 10 fold excess, is used. The other starting material used according to the invention is 2,2,4-trimethyl-l,2-dihydro-quinolinε and the compound is known from Bayer, 3. Prakt. Che . 2/33, 401/1886, and Combes, Bull. Soc. Chi . Fr. 49_, 89 (1888). The ketone condensation products of the invention are novel compounds. Due to their chemical structure they do not show a colourizing effect and can be used in a wide spectrum as antioxidaπt in the field of industry, food industry and fodder industry as well as in the field of therapy and veterinary science. The property of the new compounds by which they increase the activity of known coccidiostatics is particularly significant. We have found for instance that 2,2-di(2' ,2' ,4'-tri- methyl-1 1 ,2'-dihydroquinolin-6'-yl)-propane shows an excellent rubber antiageing activity and does not cause colouration. Similarly 2,2-di(2' ,2' ,4'-trimethyl-l' ,2'-dihydro-quinoline)- butane can be used as a non-colourizing rubber antiageing agent as it is dissolved extremely well in rubber mixtures and it can be administered even at 5 % to products being contact with food. 2,2-di(2' ,2'-dimethyl- 1 -sodium-methane sulfonate- 1' ,2'-dihydroquinolin-6'-yl)-propane is well soluble in water and can be consequently well applied in the form of injection in human therapy. The compound prevents the organism from detrimental free radical reactions. This is significant in case of poisoning, radiation injuries and disturbances of the circulation. In veterinary therapy encelophalomalatia in poultry keeping can be treated when administered the compound into the drinking water. Out of the tested new aπtioxidaπt active ingredients the toxicity of 2,2-di(2' ,2' ,4'-trimethyl-l,2' ,2 * -dihydro- quinoline)-propane is very low and it can be well applied for foddering, and food industrial and therapeutical purposes and for stabilizing organisms, as well as in animal fodders, especially as antioxidants in poultry, rabbit and pig fodders and as activity increasing components of cocciodiostatics. Even under extreme conditions (in the presence of iron, copper compounds or halides) no decolourization occurs in the nutrient or in fatty tissues. In order to prove the coccidiostatic activity increasing effect of the compound according to Example 3 it was compared with Saliπomycin^ and Monensin°. The infectedness of the animals was evaluated by 0, 1, 2, 3 crosses ( + , ++ , +++ ). The oocysta index consists of the sum of the crosses related to the total number of the animals. Table 1 Diet oocysta death body standard index weight deviation Infected control 30/10 145 41 Compound according to Example 3, 60 ppm 10/10 165 31 0 Salinomyin x Compound according to Example 3, 30 ppm . 30/10 141 27 Compound according to Example 3, Salinomycin, 120 ppm, 30 ppm 0/10 126 20 Compound according to Example 3, Salinomycin, 120 ppm, 15 ppm 0/10 141 20 Compound according to Example 3, Monensin xx , 120 ppm, 30 ppm 0/10 144 25 x Hoechst xx Eli Lilly The table shows that in case of Salinomycin^ the compound of Example 3 in a dose of 15 ppm gives the same protection, in case of Monensin the same compound at a dose of 30 ppm gives the same protection as the known compound administered per se at a dose recommended by the manufacturer. The oocysta index is determined by a known method: the oocystas are counted microscopically. 25 visual fields are tested at the same time. If the number of the oocystas counted per field is below 1, then the value is marked by + , if it is between 1-10, it is marked by ++ f above 10 the value is marked by +++ . Antioxidaπt activity On the basis of active oxygen method (AOM) 1. Description of the method Under ther ostatic conditions a uniform stream of air is passed through the samples containing and not containing antioxidant. The change of Lea-number by time is measured. 2. Used materials Glicerol trioleate puru C 5 7H 104 0 6 LOBA FEINCHEMIE K.3. p. a." Chloroform Glacial acetic acid Na 2 S 2 θ3 0.002 N solution Starch indicator 3. Test method To 4 ther ostated test cuvettes 30 g of glycerol trioleate are weighed in, in which 20 g (0.02 h) test-anti- oxidant had been dissolved. The cuvettes are maintained at 70 °C and air is passed through the test oil at a velocity of 9.6-10 1/hour. Sample is taken every hour from the control and every 4 hour from the antioxidaπt samples and Lea-number is measured as follows: To about 1 g sample 30 ml of a solution of an 1:1 chloroform and glacial acetic acid and 1 g solid potassium iodide is added, it is boiled for 60 sec, rapidly cooled and 15 ml of a 5 % aqueous potassium iodide solution is added. It is titrated with 0.002 N Na 2 S 2 0 solution in the presence of a starch indicator. (Consumption/ml 0.002 N Na2S2U3)-blank test x factor weighing in (g) 4. Results 4/1. control Time (h) 1 2 3 4 5 6 7 8 9 10 11 12 Lea number 12.4 24.9 21.624.3 38.437.352.463.3 80.085.3 108 111 4/2. Samples Time (h) 4 8 12 16 20 24 28 31 34 MTDQ comparative 6.6 '-methylene-bis- derivative (Melting point 156 °C) 17.1 22.2 26.0 29.2 32.4 42.5 55.1 73.3 95 80 % material according to Example 2 20.2 19.3 18.6 25.2 29.4 36.6 44.5 58.4 64 98 V material according to Example 4 16.3 19.4 21.0 23.5 38.5 32.0 39.1 46.3 60 acetyl derivative according to 16.9 23.2 27.8 33.0 42.6 69.2 103.5 Example 7 In case of a watersoluble antioxidant is obtained, which tested in the following heterogeneous system: 30 ml water neutralized with 1 ml phosphate puffer of pH=7. 20 g glycerol trioleate, 1.5 g 30 fatty alcohol sulponate. 20 g of the tested antioxidant agent are added to the emulsion t prepared. The weighing in of the antioxidaπt and the Lea numbers related to the oil content. Lea number/time 0 2 4 6 8 10 12 Control 2.8 6.6 9.0 26.9 72.9 124.1 267.3 S0- ? Na + - derivative 2.8 3.7 6.1 10.9 28.0 45.0 93.7 Glutathion 2.8 3.3 4.7 9.1 16.3 34.1 51.6 L-ascorbic acid 2.8 8.8 32.6 69.6 103.0 132.0 193.0 EXAMPLES Example 1 To four necked flask equipped with a stirrer and a thermometer, a feeding funnel and reflux 150 parts by weight of acetone containing 10 % water, 105 parts by weight of acetoanil, 2.5 parts by weight of pyridiπe are added and 100 parts by weight of concentrated hydrochloric acid is added dropwise. The mixture is heated to boiling point and stirred for 22 hours at this temperature. The mixture is cooled, whereafter 110 parts by weight of 40 h sodium hydroxide is added. The mixture is stirred under boiling, acetone is separated and 40 parts by weight of unreacted acetoanil are distilled off in vacuo. The butto product is (60 parts by weight) of 2,2-di(2' ,2' ,4'-trimethyl-l' ,2'-dihydro-quinol-6"- yl)-propane of 80 H purity. Melting point: 125-135 °C. Example 2 To an autoclave which can be heated by steam and cooled by water and equipped with a theremometer, stirrer and a feeding opening 100 parts by weight of acetonanil, 2 parts by weight of triethanol amine, 280 parts by weight of anhydrous acetone 106 parts by weight of concentrated hydrochloric acid are added. The equipment is closed and the content is stirred under pressure for 12 hours at 72-75 °C, then it is cooled to 40 °C and neutralized by adding 100 parts by weight of 40 h sodium hydroxide solution. The aqueous layer is removed and from the organic layer acetone is removed, whereafter acetoanil is distilled off in vacuo. Yield: 62 parts by weight of 78 H 2,2-di(2' ,2 * ,4'-trimethyl-l' ,2'- dihydro-quinol-6'-yl)-propane. Melting point: 120-135 °C. Example 3 From the antioxidaπt according to Example 1 and 2 a product is obtained in a good yield which can be recrystallized from benzene, then from isopropanol, which melts at 156 °C, is completely white and the purity of which is 96 h according to HPLC chromatography. The product shows a biological activity similar to that of the product of purity 80 %. By evaporating the mother liquour an excellent rubber ageing inhibitor is obtained. Example 4 One may proceed according to Example 1 but acetone, is replaced by methyl ethyl ketone. Yield: 45 parts by weight of 2,2-di(2' ,2' ,4 , -trimethyl-l' ,2'-dihydro-quinol-6'-yl)-butane, purity: 55 H . After recrystallization from hexane followed by isopropanol a product of purity 96-97 H is obtained melting at 117-118 °C. The product is an excellent antioxidant and its synergistic effect makes a 80 'i saving possible when used together with coccidiostatics. From the mother liquour a non- colourizing antioxidant for rubber industry can be obtained. Example 5 One may proceed as disclosed in Example 1 but as a ketone methyl isobutyl ketone is used. Yield: 20 % 2,2- di(2' ,2' ,4'-trimethyl-l' ,2'-dihydro-quinol-6'-yl)-isohexane. Purity: 50 %, melting point after recrystallization: 120- 126 °C. The product can be used similarly like the product in Example 4. Example 6 100 parts by weight of a 96 % product according to Example 3 are dissolved in 400 parts by weight of 96 % sulfuric acid, whereafter the mixture is slowly heated to • 80 °C and the reaction is performed for 2-3 hours at this temperature. The sulfonated product is added dropwise to a mixture of 1000 parts by weight of water and 1000 parts by weight of ice and the precipitated sulfonic acid is filtered. It is recrystallized from hot water in the form of free acid and then converted to sodium salt. The thus obtained colourless crystalline product is dried to constant weight. Yield: 105 parts by weight. Analysis of the product dried at 120 °C: C 55.1 V (54.91); H (5.4 H (5.42); N 4.56 % (4.75); 0 16.34 (16.27) S 10.9 H (10.85); Na 7.7 V (7.8). The product is suitable for therapeutical purposes. Example 7 The product of Example 3 is used. 100 parts by weight of this product are dissolved in 600 parts by weight of acetic anhydride and the solution is heated for 2 hours under reflux. Acetic acid and the excess of the anhydride are distilled off from the crude product and it is recrystallized from -600 parts by weight of hot acetone. Yield: 114 parts by weight, melting point: 120-121 °C, and the product is obtained in the form of pale yellow crystals.

Claims: Claims: 1. Compounds of the general Formula I and acid addition safts thereof - wherein R stands for optionally substituted C^_ 4 alkyl and R 2 stands for optionally substituted alkyl, X stands for hydrogen or SU Me - wherein Me stands for hydrogen, alkali or alkali earth metal ion, Y stands for hydrogen or acyl. 2. Compounds as claimed in Claim 1 R ? 1 1 stands for optionally substituted alkyl and R 2 stands for optionally substituted alkyl, X stands for hydrogen and Y stands for hydrogen. 3. Process for the preparation of the compounds of the general Formula I and acid addition salts thereof, which comprises condensing 2,2,4-trimethyl-l,2-dihydro-quinoline or a salt threof with a ketone of the general Formula R^R 2 C0 - wherein R-^ and R2 are as stated above - in the presence of a catalyst, such as mineral acid, preferably hydrochloric acid and of a cocatalyst, such as nitrogen-containing base, preferably triethanol amine, pyridine or aniline in a solvent and if desired converting the obtained product to acid addition salt or setting free the base from the salt and if desired sulfonating and/or acylating the obtained base. 4. Process as claimed in Claim 3, which comprises performing the condensation in an 0-40 % , preferably 10-20 h of the ketone. 5. " Process as claimed in Claim 3, which comprises using the acid preferably hydrochloric acid in a molar ratio of 0.9-2.5 mole, prefer ably 1.25-1.75 mole. 6. Pharmaceutical composition comprising as active ingredient a compound as claimed in Claim 1. 7. Fodder or fodder premix for the treatment of coccidiosis, which comprises a compound as claimed in Claim 2 next to ionophoric polyether antibiotics or salts thereof, preferably sodium salts.

Inventors: LEGRADI ILONA, MELOVITS LASZLO, OETVOES IMRE, ROZSNYAI TAMAS, SZENTE JOZSEF, SZVOBODA JANOS, LEGRADI, ILONA, MELOVITS, LASZLO, OETVOES, IMRE, ROZSNYAI, TAMAS, SZENTE, JOZSEF, SZVOBODA, JANOS
Applicants: MATERIAL VEGYIPARI KISSZOEVETK, MATERIAL VEGYIPARI KISSZOEVETKEZET
Application year: 1988
Main classification: C07D215
IPC codes: A23K1, A23K3, A61K31, C07D215, C09K15